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Abstract. We present a case of puerpera with two major complications of preeclampsia: PRES manifested by 
eclampsia and HELLP syndrome. PRES is neuroradiological entity characterized by hypertension, altered mental 
status, visual disturbances, headache and generalized seizures together with characteristic findings on cerebral 
magnetic resonance imaging scan. An important fact considering PRES (which also happened to our patient) is that it 
can be developed without significant rise in blood pressure, in a situation of severe endothelial injury with diminished 
cerebral autoregulatory capacity. Another consequence of vascular endotheliosis that developed in our patient was 
HELLP syndrome. Although the complications are severe, this state is usually completely reversible presuming that 
prompt diagnosis and adequate therapy were timely undertaken, as in the case we report here. 




Preeclampsia is a disorder that complicates 5–8% of 
all pregnancies [1–7]. Together with its most serious 
complications: pulmonary edema, acute renal failure, 
disseminated intravascular coagulation (DIC), syndrome 
of haemolysis, elevated liver enzymes and low platelets 
(HELLP), eclampsia, it is one of the leading causes of 
maternal and fetal morbidity and mortality (10–15% of 
all maternal deaths) [2, 7]. 
Genetic predisposition, immunologic intolerance 
between maternal and fetoplacental tissues and insufficient 
placentation lead to placental ischemia. This provokes 
abnormal nitric oxide and lipid metabolism, leukocyte and 
coagulation system activation, changes in various 
cytokines etc., resulting in generalized vasospasm and 
vascular endotheliosis [1, 2, 5, 6, 8–10]. Dominating 
symptom is hypertension, accompanied by significant 
proteinuria. 
In this article we present a case of puerpera with two 
major complications of preeclampsia – posterior reversible 
encephalopathy syndrome (PRES), manifested by 
eclampsia, and HELLP syndrome. 
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Case Report 
A 23 years old primipara was admitted to our intensive 
care unit (ICU) 21 hours after spontaneous term 
delivery, when she gave birth to a live male child 
(3500 g / 53 cm, Apgar score 9) in her hometown hospital. 
First sixteen hours after delivery passed uneventfully; 
suddenly she lost conscience and suffered generalized 
tonic―clonic seizure. After a few minutes she regained 
consciousness, but remained disoriented. Blood pressure 
(BP) measured at that moment was 160/100 mm Hg. 
Ninety minutes later she suffered another seizure, after 
which she was transferred to our hospital. 
On admission she was in the state of somnolence 
(during the transport she was given midasolam 45 mg), 
but oriented, able to adequately respond to our questions 
and obey commands. She claimed to be healthy till the 
day of the delivery, with no illness of any kind. She 
regularly visited her gynecologist during the pregnancy.  
Physical examination on admission showed no 
pathological signs or symptoms, other than somnolence 
and hypertension – BP was 160/100 mm Hg, pulse rate 73 
bpm. Venous blood samples were taken for hematological 
and biochemical analyses, and were repeated every day 
during her stay at our hospital.  
On admission the results of the laboratory analyses 
out of the reference ranges were as follows: Hb 86 g/l, 
Ht 27%, Plt 70  109/l, indirect bilirubin 15.2 μmol/l, 
total proteins 49.5 g/l, albumins 22.3 g/l, ALT 74 U/l, 
AST 138 U/l, LDH 1339 U/l, serum Fe 83 μmol/l, CRP 
46,9 mg/l.  
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24 hours later the results out of reference range were 
as follows: Hb 83 g/l, Ht 26.9%, Plt 103 x 10
9
/l, total 
proteins 51 g/l, albumins 26 g/l, AST 71 U/l, LDH 716 U/l, 
serum Fe 21 μmol/l, haptoglobin 0.47 g/l; reticulocytes 
10%, schistocytes on peripheral blood smear were found. 
The next day all results were in referent range, except 
Hb 75 g/l and Ht 24%.  
Endocranial MSCT was done immediately after the 
admission: irregular, partly confluent hypodensity zones, in 
cortical and subcortical white matter that might correspond 
to PRES changes were detected in parieto-occipital regions 
bilaterally. Pons, cerebellum and mesencephalon showed 
no morphological changes. No presence of blood 
endocranially. 
In order to get more subtle evaluation, magnetic 
resonance imaging (MRI) was done the next day (T1W 
sagittal, T2W/T2W FLAIR/ DW1 transversal and T2W 
coronal endocranial tomograms): zones with increased 
signal intensity, that correspond to PRES, were found in 
bilateral frontal, parietal and occipital regions in 
subcortical white matter (Figs. 1 and 2). There were no 
other pathological changes. 
 
Fig. 1. Multiple cortico-subcortical areas of T2-weighted 
hyperintense signal involving the occipital lobes 
bilaterally in axial plane 
 
Fig. 2. Multiple cortico-subcortical areas of FLAIR-
weighted hyperintense signal involving the 
occipital lobes bilaterally in axial plane 
The patient was continuously monitored: BP, pulse 
rate, oxygen saturation, temperature, diuresis. All 
parameters were in normal range, except moderate to 
severe hypertension. 
Antiedematous (sol. Manitholi 20% 125 ml/6h, 
dexamethasone 4 mg/8h), anticonvulsive (sol. MgSO4 
1g/hour), antihypertensive, antibiotic, uterotonic and 
anticoagulant - low molecular weight heparin (LMWH) 
therapy was immediately started, as well as albumin, 
electrolyte and erythrocyte supplementation (according to 
laboratory results): 
On the first day, there was one BP elevation to 
170/110 mmHg, which was treated with urapidil 50 mg 
iv. The dose was sufficient to reduce BP to 130/80 mmHg, 
so we further proceeded with peroral therapy: Captopril 
25 mg/12 hour which successfully kept BP between 
120/80 and 140/90 mmHg. 
During her stay at our Clinic, the patient had no 
eclamptic seizures, her laboratory results improved as 
well as her clinical state, so after five days she was 
transferred back to her hometown hospital. 
Discussion  
The presented case seems to be a good illustration of the 
complications that could be expected of the state we 
considered to be only the moderate form of preeclampsia. 
Preeclampsia can be manifested by wide range and 
intensity of symptoms – from severe hypertension and 
proteinuria, to mild or absent hypertension without 
proteinuria. According to recent data, 20% of women 
who developed eclampsia did not have any premonitory 
symptoms before the onset of convulsions; 16% of 
patients did not have diastolic blood pressure higher 
than 90 mmHg [11, 12].  
Our patient (per anamnesis) did not have any 
obvious typical signs of preeclampsia till after the labour. 
Sixteen hours after the delivery her state deteriorated 
suddenly (with no prodromal signs) and she had two 
episodes of eclamptic seizures. Elevated blood pressure 
was registered for the first time. PRES was diagnosed on 
MRI scan.  
PRES is a relatively new neuroradiological entity 
(first described by Hinchey at al. 1996.), characterized 
by clinical signs and symptoms of hypertension, altered 
mental status, visual disturbances, headache and 
generalized seizures together with characteristic findings 
on MRI scan [3, 13–20]. Besides eclampsia, PRES can 
occur in sepsis, after exposure to immunosuppressants, in 
autoimmune/renal/hypertensive diseases [13, 14, 21–24]. 
Underlying disorders in these conditions are immune 
system activation, inflammatory response, vascular 
instability and endothelial cell disfunction [13, 14, 17, 19, 
22–24]. 
It is supposed that rapid rise in blood pressure, in a 
state of already compromised blood brain barrier 
(endothelial dysfunction) leads to breakthrough of 
cerebral blood flow autoregulation, forced dilatation of 
cerebral vessels, cerebral hyperperfusion and vasogenic 
cerebral edema [3, 14, 21, 23, 24]. Some findings, 
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though, suggest that neurological symptoms arise from 
“overautoregulation”, vasospasm, hypoperfusion, that 
causes ischemia and, again, cerebral edema [14, 15, 21, 
23–25]. Posterior brain is less innervated with 
sympathetic fibers that regulate cerebral blood flow, so 
parieto-occipital white matter is the region where the 
edema most frequently occurs, but changes can be also 
found in frontal lobes, basal ganglia, cerebellum, and 
brainstem [14, 17, 23]. T2 weighted MRI demonstrates 
regions of higher intensity, suggestive of vasogenic 
edema [13–17, 19–21,].  
Very important fact considering PRES is that it can 
develop without a significant rise in BP [3, 14, 17, 22]. 
This is especially true in pregnancy, where the cerebral 
autoregulation curve is shifted to the lower range of BP 
[3, 14, 20, 26]. In cases of severe endothelial injury, as 
in preeclampsia, autoregulatory capability is completely 
diminished, so, as in our case, even a moderate elevation in 
BP (160/100 mmHg) can cause neurologic symptoms, 
culminating in eclamptic seizures. For that reason, in 2011, 
American College of Obstetricians and Gynecologists 
(ACOG) Committee [27] stated that: “Acute onset of 
severe systolic (more than 160 mmHg) or severe 
diastolic (110 mmHg) hypertension, or both, in pregnant 
women, persistent more than 15 minutes, is considered 
hypertensive emergency”. The most important predictor 
of cerebral injury is systolic tension [3, 5, 25].
 
 
What is encouraging about PRES is that this state is 
usually completely reversible within 7 days, presuming 
that prompt control of seizures and BP and expeditious 
delivery (in cases of prepartal eclampsia) were undertaken 
[3, 13, 14, 18, 21, 25].
 
Our therapy regimen included 
antiedematous therapy (sol. Manithol 20% 125 ml/6h, 
Dexamethasone 4 mg/8h) and anticonvulsive therapy 
(Magnesium sulfate infusion 1 g/h). Magnesium is 
considered the drug of choice for seizure prophylaxis and 
control in eclapmsia [1–3, 7, 17, 23, 26–28]. Because of 
toxic effects of hypermagnesemia (cardiac arrhythmia and 
respiratory depression), magnesemia, diuresis and deep 
tendon reflexes should be closely monitored. 
Antihypertensive therapy in pregnancy and lactation is 
highly limited, because of drug effects on the fetus as well 
as on maternal circulation. Sudden reduction of BP can 
compromise fetal-placental circulation, so, even in cases of 
emergency, only 10% BP reduction is recommended 
during first hour and another 15% gradually over next 2–
3h [29–33]. The first choice drug is intravenous labetolol, 
followed by hydralazine, nicardipine (in cases of cerebral 
vasospasm), sodium nitroprusside (only in most refractory 
cases), nitroglycerin (especially in pulmonary edema) and 
nifedipine per os [2, 4, 6, 7, 18, 26, 28–37]. Urapidil is 
allowed in pregnancy as well and it seemed to be a good 
choice in case of our patient, when raised intracranial 
pressure was presumed and cerebral vasodilatation was 
to be avoided [35, 36].
 
The urapidil dose of 50 mg was 
effective enough and allowed us to switch to peroral 
therapy with captopril 25 mg/12h. ACE inhibitors are 
contraindicated in pregnancy, but enalapril and captopril 
are allowed during lactation [5, 6, 10, 32, 34–36]. 
Considering the fact that renin–angiotensin–aldosteron 
system is also affected in preeclampsia, we chose 
captopril and had a satisfactory effect. 
The same patient suffered from another consequence 
of damaged vascular endothelium: syndrome of hemolysis 
(LDH level over 600 IU/l), elevated liver enzymes (AST 
and ALT levels higher than 70 IU/l) and low platelet count 
(below 150109 /l) – HELLP syndrome [2, 7, 38, 39]. 
HELLP is a complication in 10–15% cases of eclampsia 
and up to 20% of cases of early onset antepartum 
eclampsia [12, 40, 41].
 
It represents a serious complication 
of pregnancy that might cause maternal acute renal 
failure, peripartal hemorrhage, and fetal intrauterine 
growth restriction (IUGR), fetal thrombocytopenia, 
hemorrhage and death. HELLP demands prompt fetal 
delivery and removal of the placenta (as placenta is the 
primary cause of toxemia). Our patient had all diagnostic 
parameters of HELLP on admission. Hemolysis was 
proven by elevated LDH levels. Low haptoglobin level 
is even better marker of hemolysis; in our case the level 
was near lower limit. It would have been interesting to 
know her previous results, but unfortunately they were 
not available. Symptoms of the disease resolved rather 
quickly. We presume that it was (besides the fact that 
pregnancy was terminated and placenta, the main cause 
of the disease, removed) partly because of prompt 
treatment and may be because it was the case of late 
onset preeclampsia, which has a more favorable clinical 
course compared to the early onset preeclampsia. 
Conclusion  
We emphasized that it is important to keep in mind that 
eclampsia can develop even with moderate elevation of 
BP. If PRES is not adequately diagnosed and treated, 
ischemic cerebral injury and irreversible neurological 
damage could develop, as well as impaired cognitive 
function later in life. With prompt seizure and BP control, 
the process is completely reversible. 
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